12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tofacitinib: Phase II/III data

Pooled data from a pair of open-label extension studies - a Japanese Phase III trial and an international Phase II/III trial - in 4,102 patients with moderate to severe RA who received twice-daily 5 or 10 mg oral tofacitinib in a randomized Phase II or III trial showed that the product had a consistent safety profile and sustained efficacy over 48 months. The most common adverse events were infections and infestations (50.8%), gastrointestinal disorders (23.6%)...

Read the full 354 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >